From: Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
Responder ( n = 26)
Non-responder ( n = 16)
p value
SUVmax
2.74 ± 1.43
3.29 ± 1.47
n. s.
% ID/g
0.0022 ± 0.0009
0.0024 ± 0.0008
Skewness
0.58 ± 0.16
0.73 ± 0.24
<0.05
Kurtosis
2.39 ± 0.32
2.78 ± 0.53
<0.02
AUC-CSH
0.37 ± 0.04
0.34 ± 0.05